AWM Investment Company Inc. Makes New $996,000 Investment in Nkarta, Inc. (NASDAQ:NKTX)

AWM Investment Company Inc. purchased a new stake in Nkarta, Inc. (NASDAQ:NKTX) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 400,000 shares of the company’s stock, valued at approximately $996,000. AWM Investment Company Inc. owned about 0.57% of Nkarta at the end of the most recent reporting period.

Several other large investors have also modified their holdings of NKTX. Invesco Ltd. purchased a new stake in Nkarta in the 4th quarter valued at approximately $30,000. Sequoia Financial Advisors LLC acquired a new position in shares of Nkarta in the fourth quarter worth $31,000. China Universal Asset Management Co. Ltd. purchased a new stake in shares of Nkarta in the fourth quarter valued at $37,000. ProShare Advisors LLC purchased a new stake in shares of Nkarta in the fourth quarter valued at $45,000. Finally, Catalina Capital Group LLC boosted its stake in shares of Nkarta by 57.5% during the fourth quarter. Catalina Capital Group LLC now owns 18,818 shares of the company’s stock valued at $47,000 after acquiring an additional 6,867 shares during the last quarter. 80.54% of the stock is currently owned by institutional investors and hedge funds.

Nkarta Trading Up 5.9%

NASDAQ:NKTX opened at $1.80 on Wednesday. The firm’s fifty day simple moving average is $1.79 and its 200 day simple moving average is $2.18. The firm has a market capitalization of $127.72 million, a price-to-earnings ratio of -0.96 and a beta of 0.81. Nkarta, Inc. has a twelve month low of $1.31 and a twelve month high of $8.23.

Nkarta (NASDAQ:NKTX) last announced its earnings results on Wednesday, May 14th. The company reported ($0.43) earnings per share for the quarter, beating the consensus estimate of ($0.44) by $0.01. On average, analysts predict that Nkarta, Inc. will post -1.7 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on NKTX shares. HC Wainwright reissued a “buy” rating and issued a $18.00 target price on shares of Nkarta in a research note on Thursday, March 27th. William Blair reissued a “market perform” rating on shares of Nkarta in a research report on Thursday, May 15th. Needham & Company LLC decreased their target price on shares of Nkarta from $11.00 to $10.00 and set a “buy” rating on the stock in a research report on Thursday, May 15th. Finally, Stifel Nicolaus dropped their price objective on shares of Nkarta from $15.00 to $14.00 and set a “buy” rating for the company in a research note on Thursday, March 27th. One analyst has rated the stock with a hold rating, five have given a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, Nkarta has a consensus rating of “Buy” and a consensus target price of $14.67.

About Nkarta

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.